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1. Introduction 
P2X receptors are membrane non-selective cation channels that gated in the presence of 
extracellular adenosine triphosphate (ATP) and related di- and tri-phosphate nucleotides, 
that more commonly known for providing cells with energy. Binding of ATP to the 
excellular pocket of P2X triggers the opening of transmembrane pore, which allows sodium, 
magnesium, potassium, calcium and other organic ions to flow down their electrochemical 
gradients. Because seven P2X receptor subtypes (P2X1-7) are widely distributed in excitable 
and nonexcitable cells of vertebrates, P2X receptors mediate many physiology processes 
including synaptic transmission and thrombocyte aggregation. These ion channels are also 
involved in the pathology of several disease states, playing key roles in inter alia afferent 
signaling (including neuropathic pain), regulation of renal blood flow, vascular 
endothelium, and chronic inflammation, and thus are potential targets for drug 
development. The recent discovery of potent and highly selective antagonists for P2X 
receptors, through the use of high-throughput screening, have helped to further understand 
the P2X receptors pharmacology and provided new evidence that P2X receptors play 
specific roles, such as in chronic pain states. In this review, we place previous work of P2X 
in the context of three-dimensional (3D) crystal structure of Zebrafish P2X4.1 (ΔzfP2X4.1), 
discuss how the P2X family of ion channels have distinguished themselves as potential new 
drug targets, and try to differentiate between drugs which are useful research tools, helpful 
in understanding the physiological roles of these receptors. We also summarize the key 
questions and challenges, which await researchers’ further work as we move forward to the 
new drug development era of P2X receptors. We are optimistic that safe and effective 
candidate drugs will be suitable for progression into clinical development.  
2. The P2X receptor protein family 
2.1 The gene of P2X receptors 
Seven P2X receptor subtypes in mammals are different in genes. Their chromosomal 
locations, amino acid length and mass are summarized (Table 1). P2X2, P2X3 and P2X6 
receptor genes are all on different chromosomes. P2X1 and P2X5 subunit genes are located 
close on the short arm of chromosome 13 (Table 1). P2X4 and P2X7 subunit genes are also 
both located on the long arm of chromosome 12 (North 2002). From the alignment of amino 
acid sequences, P2X4 and P2X7 are the most related pairs (North 2002). The full-length of 
seven P2X receptors have 11-13 exons, and they all share a common structure, with well-
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conserved amino acids in the outer loop and transmembrane regions. These seven genes are 
considerable different in size.  
 
Subunit Chromosome Length (AA) Mass (Da) Accession 
Nos. 
Reference Nos. 
P2X1 17p13.2 399 44,980 P51575 (Longhurst PA 1996, Soledad 
Valera 1994) 
P2X2  471 51,754 Q9UBL9 (Kevin J. Lynch 1999, Lynch et 
al. 1999) 
P2X3 11q12 397 44,289 P56373 (Garcia-Guzman et al. 1997b) 
P2X4 12q24.31 388 43,369 Q99571 (Garcia-Guzman et al. 1997a) 
P2X5 17p13.3 422 47,205 Q93086 (Le et al. 1997) 
P2X6 22q11 441 48,829 O15547 (Urano et al. 1997) 
P2X7 12q24.31 595 68,586 Q99572 (Franc¸ois Rassendren 1997) 
Table 1. Properties of human P2X receptors 
Chromosomal localizations, amino acid length, and Mass are from Protein Knowledge base 
of UniProtKB (http://www.uniprot.org/). The accession numbers and references are 
indication for the original submission of cDNA sequences. 
2.2 Amino acid sequence and structure 
In the mid-1990s, the first cDNA cloning of P2X receptor led to the deduction of P2X 
receptors’ structure and physiology. In 2009, Kawate and colleagues reported the crystal 
structure of a truncated mutation of the Zebrafish P2X4.1 receptor (ΔzfP2X4.1) (Toshimitsu 
Kawate 2009), which is the first 3D crystal structure of P2X receptors. It represents a step 
change in our understanding of these membrane ion channels, where previously only low-
resolution structure data and inferences from indirect structure-function studies were 
available. Due to these indirect and direct biochemical and pharmacological data, 
approximate structure and topology of seven distinct P2X1–P2X7 subtypes can be elucidated. 
Three individual subunits assemble to form functional homomeric (except P2X6) or 
heteromeric receptors (except P2X7). These subunit peptides are difference in size ranging 
from 388 (hP2X4) to 595 (hP2X7) amino acids long. The protein of these seven subtypes are 
pairwise identical (from 40% to 55%) (North 2002). All functional P2X receptors have the 
following topology: intracellular N-terminus/first transmembrane segment 
(TM1)/extracellular segment/second transmembrane segment (TM2)/intracellular C-
terminus. 
2.3 TM domains and the pore region 
Every P2X protein has two hydrophobic transmembrane regions, which are sufficient long 
to cross the plasma membrane (Brake et al. 1994, North 1996, Valera et al. 1994). The 
presences of only two transmembrane segments distinguish P2X receptors from other 
ligand-gated cation channels. The first transmembrane segment (TM1) extends from residue 
30 to 53, and the second transmembrane segment (TM2) from 328 to 353 (in the rat P2X2 
receptor) (Zhiyuan Li 2004). These two regions are both ǂ-helix, form the central ion 
conduction pore and participate in the conformational changes during receptor activation. 
Three pairs of TM1 and TM2 domains are highly tilted to the cell membrane giving the pore 
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Fig. 2. Structure of P2X receptors. (a) Topology features of P2X receptors which based on the 
structure-function studies on P2X1 and P2X2 receptors. The numbers refers to rat P2X2 
receptors. (b) Stereoview of the homotrimeric ΔzfP2X4 structure. Three subunits are 
depicted in red, yellow and blue, respectively. NAG and glycosylated asparagines residues 
are represented in stick. This is a closed resting conformation. (c) Top view of the 
homotrimeric ΔzfP2X4 structure from extracellular side of the membrane. Fig. a is 
reproduced from reference (North 2006). Fig. b-d are reproduced from reference 
(Toshimitsu Kawate 2009). 
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an hourglass appearance (Toshimitsu Kawate 2009). The previous mutagenesis, functional 
work and 3D crystal structure give strong evidence that the TM2 domain plays major role in 
ion transduction and pore opening. TM2 domain is directly involved in the assembly of 
subunits into oligomeric complexes and is partly responsible for determining the rate and 
degree of desensitization (Evans 2010), interacts with the permeating ions and regulates 
specific properties of ion flow including conductance (Nakazawa et al. 1998), permeability 
(Migita et al. 2001), and Ca2+ flux (Egan et al. 2004) among P2X receptors. The diameter of 
the narrowest part of the open pore is thought to be about 8-20 Å (Toshimitsu Kawate 2009), 
which is from Thr 336 to Phe 346 (the number refers to rat P2X2) (Mufeng Li 2008). Although 
the present data suggest that the TM1 domain involved in transducing agonist binding into 
channel gating, an explicit role for the TM1 has not been identified. The COOH- and NH2-
terminal regions are both in the cytoplasm.  
2.4 Terminal regions 
The N-terminus region is relatively short (about 25 amino acids) and contains a consensus 
site for protein kinase C-mediated phosphorylation; removal of this site leads to an 
accelerated fade in the amplitude of the ATP-gated current of the P2X2 receptor. The C-
terminus is longer (about 25–250 amino acids) and diverges in sequence considerably 
between seven subtypes and contains multiple sites that mediate subtype-specific effects. A 
YXXXK motif at the end of the TM2 is highly conserved among all P2X receptors, the Tyr 
and Lys of which have been proved to stabilize the P2X subunit in the plasma membrane, 
which was reported by Rassendren and his colleagues (Chaumont et al. 2004). 
2.5 Extracellular domains 
The extracellular loop also contains consensus sequences for the N-linked glycosylation 
involved in targeting the receptor to the cell surface membrane, for agonist and antagonist 
binding sites, and for intersubunit binding sites responsible for allosteric modulation of the 
ATP response by hydrogen ions and zinc. 
The two transmembrane segments are connected by a long string of amino acids that form 
the extracellular of the receptor. This string contains ten conserved cysteines, which 
participate in disulfide bonds that help define the tertiary structure of the protein. From the 
N-terminus to the C-terminus, the cysteine pairs are 1-6 (Cys119 – Cys168), 2-4 (Cys129 – 
Cys152), 3-5 (Cys135 – Cys162), 7-8 (Cys220 – Cys230) and 9-10 (Cys264 – Cys273). These ten 
cysteine residues are very conserved in all mammalian P2X receptors (Clyne et al. 2002, 
Ennion et al. 2002). Two pairs of disulfide bonds which are pair 2-4 and 3-5, may exchange 
with each other during and after biosynthesis, because of the very close space. 
Based upon mutagenesis data and binding studies, eight highly conserved residues have 
been proved to be involved in ATP binding. In rat P2X2 these residues are Lys74, Lys76, 
Phe188, Thr189, Asn293, Phe294, Arg295, and Lys313 (Jiang et al. 2000, Marquez-Klaka et al. 
2007, Roberts et al. 2004, 2006). In the 3D crystal structure of ΔzfP2X4.1, these residues are 
lining a cavity which is surrounded by the head domain, and left flipper of one subunit, and 
dorsal fin of another (Toshimitsu Kawate 2009). The exact nature of these residues is not 
very clear so far. How do they interact with each other is unknown. Jiang and Roberts 
reported that the negatively charged triphosphate moiety may interact with positively 
charged residues Lys74, Lys76 and Lys313, whereas Phe188, Thr189, Asn293, and Phe294 
might be interacted with the adenine ring and ribose moiety (Roberts et al. 2006). 
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All seven P2X receptor subtypes have consensus sequences for N-linked glycosylation (Asn-
X-Ser/Thr) some of which is essential for protein to traffic to the cell surface. In rat P2X2, 
Asp182, Asp239 and Asp298 all can be glycosylated in oocytes and HEK293 cell (Newbolt et 
al. 1998). If these glycosylation sites are removed or prevented by tunicamycin or 
mutagenesis, the full function of P2X receptors will be disturbed. Receptors give no 
response to ATP, if only one site is glycosylated. But if two of three sites are glycosylated, 
the cell can express full function receptors (North 2002). All P2X receptors have N-linked 
glycosylation, which are well conserved among species but different between receptor 
subtypes (North 2009., North 2002). 
3. Physiological role of P2X receptor 
Seven P2X receptor subunits (P2X1−7) are widely expressed in tissues throughout body; for 
example, they are found in excitable and nonexcitable cells, such as neurons, myocytes, 
leukocytes and epithelial cells. And thus they play key roles in inter alia afferent signaling 
(including pain), regulation of renal blood flow, vascular endothelium, and inflammatory 
responses. Most P2X receptors are nonselective cation channels that discriminate poorly 
among monovalent cations, while exhibiting a stronger preference for calcium ions. The 
exception is P2X5 receptor, which in some species such as human and chicken exhibits a 
modest permeability for chloride ions. The resulting rise in intracellular calcium evokes 
transmitter release from central and peripheral neurons and glia, promotes hormone release 
from endocrine glands, triggers contraction of muscle, regulates airway ciliary motility, and 
activates downstream signaling cascades in various of cells.  
3.1 Central nervous system 
ATP is a fast neurotransmitter, it can be released from the excitable and nonexcitable cells in 
normal physiological and pathophysiological conditions. As one member of the purinergic 
receptor family, P2X receptors are widely expressed on central nervous system at different 
mRNA and protein levels, for example, P2X2, P2X4 and P2X6 are most abundant in neurons 
(North 2006). They play an important role in the regulation of neuronal and glial functions, 
which is participating in the synaptic process and mediating communications among them. 
In the central synapses, the significant function of P2X may be related to depolarizing 
neurons and considerable calcium permeability plays the key role (Pankratov et al. 2002), no 
matter it is at resting membrane potential or not.  
3.1.1 Postsynaptic and presynaptic 
Using post embedding immunocytochemistry, Rubio and his colleagues for the first time 
qualitatively and quantitatively described the precise location of P2X2, P2X4 and P2X6 
subunits in postsynaptic on the hippocampal CA1 pyramidal and cerebellar Purkinje cells 
(Rubio et al. 2001). Bouts of action potential firing are activated the synaptic P2X receptors.  
The function and densities of P2X receptors in the postsynaptic might be related to some 
specific proteins. Using the glutathione S-transferase pull-down experiment, it is proved 
that ǃ-amyloid precursor protein-binding proteins Fe65 colocalizes and interacts with P2X2 
receptor in postsynaptic of excitatory synapses (Masin et al. 2006). Direct postsynaptic 
effects on neurons have been reported.  
Khakh and Gu have reported that P2X receptors mediate presynaptic responses. Calcium 
ions play a key role in this responses, which are triggered and enter through the P2X 
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receptors or through Ca2+ channels (North 2006). Presynaptic P2X receptors may be active 
physiologically in some synaptics (Gu et al. 1997). Presynaptic actions form one component 
of ATP effects in hippocampus. A feed forward circuit forms among the CA3 pyramidal 
neurons, GABAnergic interneurons and output CA1 pyramidal neurons. The increased 
release of glutamate from presynaptic P2X2 receptors works on the interneurons, which are 
depolarized by P2Y1 receptors. The depolarization of interneurons is the concomitant 
reduction and activation of potassium and nonselective cationic conductance, respectively 
(Bowser et al. 2004, North 2006). ATP plays a special role in this feed-forward circuit, it 
might act as a physiological brake to runaway excitation. 
3.1.2 Disorder  
Because the ATP plays key roles in neurotransmission and neuromodulation, purine and 
pyrimidine receptor subfamilies have been involved in various pathological conditions. This 
pathophysiology of CNS disorders include brain trauma, ischaemia, neurodegenerative 
diseases and neuropsychiatric diseases. When injury happens, large amounts of ATP release 
into extracellular environment which are important for triggering cellular responses to 
trauma. The expression level of P2X4 and P2X7 has changed, which might stimulate the 
migration and chemotaxis of resting microglia to the site of damage (Ohsawa et al. 2007, 
Xiang et al. 2006), and P2X7 have an important role in controlling microglia proliferation and 
death (Bianco et al. 2006, Franke et al. 2006). Cerebella lesions result in up-regulation of P2X1 
and P2X2 receptors in precerebellar nuclei, and stab wound injury in the nucleus accumbens 
leads to increased expression of several subtypes of P2X and P2Y receptors. 
Cerebral ischaemia can produce and exacerbate problems to the CNS, which include stroke 
and paralysis. This disease can increase the release of purines into cerebral cortical 
perdusates (Braun et al. 1998). In vitro studies of organotypic cultures from hippocampus, F. 
Cavaliere and their colleague found out that P2X2 and P2X4 were up-regulated by 
glucose/oxygen deprivation (Cavaliere et al. 2003), and this can be prevented by P2 receptor 
antagonists. On the other side, P2X4 and P2X7 receptors, which are on microglia, and may be 
involved in cortical damage, also produced by glucose/oxygen deprivation (Cavaliere et al. 
2005). 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral 
sclerosis (ALS) are all belong to neurodegenerative diseases. P2X7 receptor is related to 
Parkinson’s disease and Alzheimer’s disease, but the function of P2X7 in the pathogenesis of 
the Parkinson’s disease is not very clear. However, the animal model and patients with 
Alzheimer’s disease showed that P2X7 receptor is up regulated in the brain (McLarnon et al. 
2006, Parvathenani et al. 2003). P2X7 in microphages and microglia might enhance the 
degenerative (Rampe et al. 2004). Changes in P2X receptor-mediated neurotransmission in 
cortico-striatal projections have been found in two different transgenic models of 
Huntington’s disease (Burnstock 2008, Burnstock et al. 2011). The density of P2X3, P2X6, and 
P2X7 might be related to Diabetic neuropathy. On the diabetic rats, it is found out that they 
decreased in hippocampal nerve terminals.  
Epilepsy seizures have devastating behavior. The pathogenesis is still unclear. P2X receptors 
play important roles in this disease, especially for P2X7. The decrease of presynaptic P2X 
receptors in the hippocampus of rats might be related to the development of seizures and 
neurodegeneration during epilepsy (Burnstock 2008). Abnormal expression of P2X7 might 
be associated with immunoreactivity in hippocampus and microglia (Rappold et al. 2006). 
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3.2 Genitourinary system 
The vitro and vivo experiments showed that ATP and its analogues alter renal vascular 
resistance and renal blood flow. Seven P2X receptors are expressed in renal vascular, 
glomerular, mesangial and tubular epithelial cells. For example, P2X1 expressed in 
preglomerular arteries and afferent arteriole (Turner et al. 2003, Zhao et al. 2005), whereas 
P2X2 are expressed in larger intrarenal arteries (Turner et al. 2003). P2X4 and P2X7 are all 
detected in medium arteries (Lewis et al. 2001). 
The recent hypothesis is P2X1 receptors play an important role in renal autoregulation via 
tubuloglomerular feedback. Using the immunohistological studies, it has been detected 
that P2X1 expressed in afferent arterioles, if the glomerular filtration rate or the rate of 
reabsorption in the proximal tubule changes; the glomerular filtration rate will change 
correspondingly. Changes in glomerular filtration rate are sensed by macula dens cells 
which will release ATP to stimulate P2X1 receptors on afferent arteriolar smooth muscle 
(North 2009). This process triggers an increase of afferent arteriolar resistance. This 
reduces pressure in the glomerular capillaries and decreases glomerular filtration (Guan 
et al. 2007). 
 
 
Fig. 3. Bladder urging, general view of bladder emptying. Stretching releases ATP from the 
inside of bladder epithelia cells, and channels made of P2X3 receptors could detect ATP and 
trigger the neuronal pathway which responses for the bladder emptying. Fig.3 was 
reproduced from reference (McCleskey 2000 ) 
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Why we feel urge? The P2X3 receptor knockout mice proved that P2X3 receptors which are 
expressed only on sensor neurons, detect extracellular ATP, that is proposed to be released 
from the urothelium as a sensory mediator for the degree of the urinary bladder distention 
(Ferguson et al. 1997). If P2X3 receptors are knocked out, the mice performed greatly 
decreased responses to the filling and stretching of urinary bladders, this means that they 
emptied their bladder less frequently than wild type. This urine storage disorders might be 
treated by antagonists of P2X3 receptors. 
Purinergic nerve-mediated contraction of the human bladder is increased to 40% in 
pathophysiological conditions such as interstitial cystitis (IC), outflow obstruction, 
idiopathic detrusor instability and probably also neurogenic bladder (Burnstock et al. 2011). 
Using bladder tissue sample of patients undergoing cystectomy or prostatectomy, Tempest 
et al found out that P2X2 and P2X3 receptors are all expressed in human bladder urothelium. 
Their protein expressing level did not correlate with the gene expression, which might be 
related to the pain with IC (Tempest et al. 2004). 
3.3 Taste 
A single taste bud contains three of four types of taste cells, including type I supporting 
cells, type II receptor cells, and III presynaptic cells, type IV basal cells. Type I cells on the 
outside of the type II and III. P2Y and P2X receptors are expressed on the type II cells, which 
are for the five tastes (umami, sour, salty, sweet and bitter), but type II cells do not synapse 
with afferent nerves within the taste buds. In taste system, ATP is a key neurotransmitter, 
which bridge between the taste bud and the nervous system. RT-PCR and 
immunohistochemical studies confirmed that P2X2, P2X3, P2X4, P2X7 receptor expressed on 
the taste bud cell. P2X2 localized on the afferent nerve fibers and presynaptic cells, P2X3 only 
localized afferent fibers, but the immunohistochemical studies showed no P2X4 protein in 
taste bud cells and nerve fibers (Hayato et al. 2007, Kataoka et al. 2006). Homomeric and/or 
heteromeric P2X2 and P2X3 receptors play an important role in taste transduction. Finger 
and his colleagues found out that P2X2 and P2X3 knockout mice decreased the responses to 
sweet, glutamate and bitter substances (Finger et al. 2005). But single knockout mice recover 
some neural and behavioral responses to tastants (Finger et al. 2005). The exact role of P2X7 
is still not very clear, but it might be related to taste bud cells apoptosis (Hayato et al. 2007). 
3.4 Hearing  
Studies on the animal (rat, mouse) showed that P2X2 and P2X3 receptors might be in the 
inner and outer hear cells. This is only electrophysiological and immunolocalization data. 
There is no knockout animal model data to confirm the exact function of these P2X 
receptors. 
3.5 Cardiovascular diseases 
It has been reported that P2X receptors expressed throughout the cardiovascular system. In 
recent years, two tissues (the platelet and the endothelium) are studied in blood pressure 
and blood coagulation have advanced rapidly.  
Although it has a long history that P2Y1 and P2Y12 play a main role in thrombosis, the P2X1 
receptors might play an important role in thrombus formation under the condition of 
stenosis, in which shear stress is high. It has been proved by the P2X1 knockout animal 
model which is platelet-dependent thrombotic occlusion of small arteries. In this model 
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blood flow is characterized by a high shear rate. In the model of systemic thromboembolism 
death rate of P2X1 deficient mice is reduced and the size of mural thrombi was decreased 
compared to the wild type, mural thrombi was made by laser induced vessel wall injury 
(Hechler et al. 2003). It is also contribute to transient Ca2+ influx and platelet shape change in 
response to ATP or Alpha, beta-MeATP and responsible for the platelet activation induced 
by low concentrations of collagen (Gachet 2008, Rolf et al. 2001, Rolf et al. 2002). This makes 
the P2X1 receptors represent the ideal target for an antithrombotic drug. 
As we all know, ATP is a cotransmitter in the heart, which is released from ischemic and 
gypoxicmycytes. Using quantitative PCR and situ hybridization, Musa and colleagues 
measured expression of mRNA of the P2X receptors in rat left ventricle, right atrium, 
sinoatrial node (SAN), and human right atrium. It is found out that P2X5 was expressed 
abundantly in all three regions of rat heart. Although in human right atrium and SAN 
mRNA of P2X4-7 was expressed, the expression of P2X4 and P2X7 mRNA was highest in 
these two regions. P2X1 mRNA was only detected in human SAN (Musa et al. 2009). The 
increased expression of P2X1 in the atria might be contributed to suffer from dilated 
cardiomyopathy. That P2X4 mRNA was up-regulated contribute to ligation-induced heart 
failure (Burnstock et al. 2011, Musa et al. 2009). 
Endothelial P2X4 receptors play a crucial role in flow-sensitive mechanisms, which regulate 
blood pressure and vascular remodeling. It has been proved by Yamamoto et.al on the P2X4 
deficient mice model. P2X4 knockout mice didn’t have normal endothelial cell responses to 
flow, for example, Ca2+ influx and production of the potent vasodilator nitric oxide (NO) 
which might lead to higher blood pressure (North 2009), and it is also found out that P2X4 
deficient mice excrete smaller amounts of NO in urine than wild type (Yamamoto et al. 
2006). 
3.6 Respiratory system 
ATP is playing a crucial role in the central respiratory control, which might mediate changes 
in the activity of medullary respiratory neurons in hypercapnia. Gourine and colleagues 
found out the evidence that ATP acting on P2X2 receptors, which are expressed in 
ventrolateral medulla that contains respiratory neurons responsible for generating and 
shaping the respiratory rhythm. Modulation of the function of P2X2 receptors in 
ventrolateral medulla might be related to change in activities of ventrolateral medulla 
respiratory neurones (Gourine et al. 2003).  
It has also been discovered that P2X4 receptors expressed on lung epithelial cells can control 
ciliary beat frequency, which make the clearance of mucus from the airways (Zsembery et 
al. 2003). Cystic fibrosis might be benefit from manipulation of it. Some agonists, such as ǃ2-
adrenergic (P2Y2 agonist) and ATP, can increase ciliary beating in trachea and airway 
epithelia via activation of P2Y and P2X receptors, which provide an key therapy in 
respiratory diseases (Leipziger 2003). Zhao et al found out that erythromycin can block P2X 
mediated Ca2+ influx, this action of which might contribute to the treatment of airway 
inflammation. 
3.7 Exocrine glands 
Exocrine glands can secrete hormones and other chemical messengers into ducts that lead 
directly into the external environment. ATP work on the purine receptors that are expressed 
on secretory epithelia with the consequent secretion of hormonal peptides, bicarbonate, 
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potassium and so on (Leipziger 2003). Pochet and colleagues found out that P2X7 receptors 
are expressed in mice submandibularductal cells, and P2X4 receptors are also involved. 
Using the wild type and P2X7 knockout mice models, they found out strong evidence that 
P2X7 salivary secretion through the modulation of phospholipid signaling processes, 
especially for phospholipase A2 and phospholipase D. In the knockout mice, ATP no longer 
active any phospholipid signaling and saliva showed a decreased potassium content 
(Garcia-Marcos et al. 2006). Using the RT-PCR and immunohistochemical staining, it is 
found out that P2X4 receptors are in choangiocytes, which is likely the primary isoform 
involved, representing a functionally component which modulating biliary secretion 
(Doctor et al. 2005). 
3.8 Intestinal motility 
There is some evidence show that P2X receptors are expressed in the enteric nervous 
system, which underlies coordinated movements of the intestine. P2X2, P2X3 and P2X7 
receptors are all involved in the intestine system in health and gut disease. It has been 
detected that P2X2, P2X3 receptors are expressed on AH cells which is the principal intrinsic 
afferent neuron of the enteric nervous system (Furness et al. 2004, North 2009). In the P2X3 
knockout mice model, the gut peristalsis was inhibited. It has been proved that P2X3 
receptors might contribute to detection of distention or intraluminal pressure increases and 
initiation of reflex contractions (Bian et al. 2003). On the other side, P2X3 receptors are 
involved in gut disorders. Irritable bowel syndrome (IBS) is characterized by chronic 
abdominal pain, bloating and discomfort. In the rat model of IBS-like visceral hyperalgesia, 
P2X3 protein expression was significantly enhanced in colon-specific DRGs 8 weeks (Xu et 
al. 2008), which suggesting a potential role in dysmotility and pain (Yiangou et al. 2001). 
Wynn et al described that P2X3 receptors signaling enhancement in colitis (Wynn et al. 
2004). It is suggesting that P2X3 receptors are potential targets for drug development of IBS. 
P2X3 receptors are expressed in intrinsic sensory neurones in the submucous plexus of gut 
and extrinsic sensory nerves (Xiang et al. 2004). It has been found out that in the substantial 
distension, ATP activates moderate distension higher threshold extrinsic sensory fibers and 
lower threshold intrinsic enteric sensory fibers that transmit the message to the CNS, via 
P2X3 receptors from mucosal epithelia, respectively (Bian et al. 2003, Wynn et al. 2004, Wynn 
et al. 2003). 
3.9 Immune system and inflammation 
It is found out that P2X1, P2X4 and P2X7 receptors are coexpressed in most immune cells in 
different level. P2X7 receptors play a crucial role in inflammation and immunomodulation 
(Burnstock et al. 2011).  
Inflammation is initiated by some pathogen constituents, injured or dying cells which can 
release intrinsic host molecular (Di Virgilio 2007). As the host endogenous pro-inflammatory 
Nucleotides especially ATP play a key role in inflammation in which human IL-1 family 
proteins are key mediators of the acute immune response to injury and infection. The P2X7 
receptor is the key player in interleukin (IL)-1ǃ and IL- 18 maturation and release. In 
inflammation process, P2X7 receptors induce the rapid activation of caspase-1 with 
subsequent release of the pro-inflammatory cytokine IL-1ǃ from activated macrophage and 
microglia. That inhibition the P2X7 receptor is directly decreased the levels of IL-1ǃ in 
plasma or in the area of injury. 
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Fig. 3. P2X7 receptor and the NALP3 inflammasome. The P2X7 receptor is the key player in 
interleukin (IL)-1ǃ and IL-18 maturation and release. High concentrations of extracellular 
ATP, present at sites of inflammation, activate a P2X7R/pannexin-1 protein complex which 
induces the rapid activation of caspase-1 with subsequent release of the pro-inflammatory 
cytokine IL-1ǃ from activated macrophage and microglia. This figure is reproduced from 
reference (North 2009).  
Mycobacterium tuberculosis (MTB) is a monocyte/macrophage (M/M) parasite. Lammas 
and colleagues proved that P2X7 receptors associated with ATP induced apoptosis in 
macrophages that result in killing of the mycobacteria within them (Lammas et al. 1997). 
Roberta et al also proved that mycobacterial infection leads to an increased expression of 
P2X7, and at the same time infected macrophages induced the extracellular release of ATP. 
Cell death can’t be induced by MTB after using the oxidized ATP (oATP), which is the P2X7 
receptor antagonist (Placido et al. 2006). Taken together, the death of intracellular bacilli 
directly related to P2X7 mediated macrophage apoptosis, but the mechanisms underlying 
the IL-1 cytokines (IL-1ǂ, IL-1ǃ and IL-18) cellular release are still unclear. Pelegrin and 
colleagues investigated the release patterns in LPS-primed peritoneal macrophage, 
RAW264.7 macrophage, and J774A.1 macrophage. They found out that IL-1ǃ is the direct 
cause of macrophage apoptosis, and two release pathways are proved (Pelegrin et al. 2008). 
One is the caspase-1 mediating release of processed IL-1ǃ that is selectively blocked by 
inhibition of caspase-1 or panx1, the other is a calcium independent, caspase-1/ panx1-
independent release of pro-IL-1ǃ that is selectively blocked by glycine (Pelegrin et al. 2008). 
Although it is proved that P2X7 receptors are highly expressed in these macrophage, 
apoptosis of which is related to its prolonged activation, and concomitant killing of 
intracellular pathogens (North 2009, Pelegrin et al. 2008), it is unclear that whether the 
macrophage apoptosis is necessary for killing of intracellular mycobacteria. 
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Receptors Distribution Antagonist Diseases and potential 
therapeutic  
strategies 
P2X1 Sympathetic neurons, Sensory neurons, 
Smooth muscle, Cardiac muscle, 
Endothelial cells, Inner ear, Osteoblasts, 
Platelets, Cochlea Oligodendrocytes, 
Exocrine secretary cells, Kupffer cells  
Ip5I, MRS 2220, 
NF023 
 
P2X2 Sympathetic neurons, Sensory neurons, 
Eye, Tongue, Parasympathetic neurons, 
Enteric neurons, Central nervous system, 
Retinal neurons, Endothelial cells, 
Osteoblasts, Keratinocytes, Sperm, 
Erythrocytes, macrophages, Endocrine 
secretory cells, Cholangiocytes, Inner ear, 
Olfactory organ, Cochlea  
  
P2X3 Sympathetic neurons，Tongue, 
Parasympathetic neurons, Keratinocytes, 
Müller cells, Sensory neurons, Enteric 
neurons, Retinal neurons, Smooth 
muscle, Cardiac muscle, Endothelial cells, 
Inner ear, Cholangiocytes  
A-317491, 
TNP-ATP, 
 
neuropathic and 
inflammatory animal 
pain (Jarvis et al. 2002) 
thermahyperalgesia 
and mechanical 
allodynia, ATP-induced 
allodynia (Nakagawa et 
al. 2007) 
P2X4 Sympathetic neurons, Parasympathetic 
neurons, Enteric neurons, Central 
nervous system, Retinal neurons, Cardiac 
muscle, Osteoclasts, Epithelial cells, 
Microglia, Müller cells, Endothelial cells, 
Erythrocytes, Immune cells, 
Exocrine/Endocrine secretory cells,  
Suramin, 
PPADS, 
Reactive Blue 
2, CORMs 
 
P2X5 Sympathetic neurons, Parasympathetic 
neurons, Sensory neurons, Retinal 
neurons, Smooth muscle, Cardiac muscle, 
Osteoblasts, Keratinocytes, Epithelial 
cells, Müller cells 
  
P2X6 Sympathetic neurons, Central nervous 
system, Smooth muscle, Cardiac muscle, 
Epithelial cells, Cholangiocytes 
  
P2X7 Sympathetic neurons, Sensory neurons, 
Enteric neurons, Central nervous system, 
Retinal neurons, Smooth muscle, Eye, 
Osteoblasts, Keratinocytes, Fibroblasts, 
Epithelial cells, Microglia, Cochlea, 
Müller cells, Enteric glial cells, Sperm, 
Erythrocytes, Immune 
cells(predominantly), Inner ear, Kupffer 
cells, Exocrine/Endocrine secretory cells 
AZD9056 
(clinic trial Ⅱ), 
KN62, Brilliant 
Blue, oATP, A-
438079,  
PPADS, 
Suramim, 
Decavanadate 
rheumatoid arthritis 
(Elsby et al. 2011) 
Parkinson disease 
(Marcellino et al. 2010) 
antinociception 
(McGaraughty et al. 
2007) 
Table 2. Characteristics of P2X receptors 
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Osteoclasts function in concert with osteoblasts, fibroblast lineage cells which deposit new 
bone. Normal bone remodeling and the maintenance of skeletal integrity need osteoblasts 
and osteoclasts coordinate their activity. Using extracellular monoclonal antibody, Gartland 
et al. performed an experiment in vivo and in vitro, which demonstrated that P2X7 receptors 
are expressed in various stages of osteoclast differentiation (Gartland et al. 2003). 
Osteoclastresorptive activity was inhibited by its antibody. Comparing the P2X7 knockout 
mice model with wild type, it is indicating that P2X7 does not regulate longitudinal bone 
growth, but P2X7 knockout mice significantly reduced in total and cortical bone content and 
periosteal circumference in femurs (Ke et al. 2003). Thus, the P2X7 receptor represents a 
novel therapeutic target for skeletal disorders. 
4. Novel therapeutic drugs 
Since seven P2X receptors (P2X1-7) are widely distributed in excitable and non-excitable cells 
of vertebrates, and play a crucial role in the pathology of several disease states, such as 
neuropathic pain, chronic inflammation, rheumatoid arthritis and so on. Thus P2X receptors 
are the potential targets for drug development. Considerable efforts have been made to 
synthesize therapeutic antagonists. Besides being important pharmacological tools for 
characterization of the pathophysiological roles of P2X receptors in native systems, such 
ligands may represent new therapeutic entities of potential interests in various human 
diseases. The most prospective areas for drug discovery at present are for the treatment of 
visceral pain with P2X3/P2X2/3 receptor antagonists and neuropathic and inflammatory pain 
with P2X7 antagonists up to present. 
4.1 P2X7 receptors 
P2X7 receptors is a unique family have been extensively studied in immune cells where they 
are related to rapid release of pro-inflammatory cytokines and the initiation of the 
inflammatory cascade. Until now there are some therapeutic antagonists have been 
synthesized. They are evaluated in different levels from animal model experiment to clinical 
trial. Some of them are still evaluated in cell test as a tool for pathophysiological study. The 
P2X7 receptors antagonists are nonselective or selective, and they show different affinity and 
IC50. 
The most promising P2X7 receptor antagonist is AZD9056, which was developed for oral 
treatment of rheumatoid arthritis. AZD9056, a weakly basic secondary amine (pKa 9.77) 
with a hydrophobic adamantine moiety that is highly protein bound (97%), is in clinic trial 
Ⅱ (Elsby et al. 2011). Efficacy and drug-drug interaction (DDI) studies performed as part of 
the clinical development program for a new candidate drug. This study is prior to patient 
studies. Since patients with rheumatoid arthritis receive multiple co-medications, that might 
be taken a risk of the co-morbid conditions, it is necessary to evaluate the potential of RA 
drug candidates to perpetrate a drug-drug interaction (DDI) with methotrexate which is a 
most commonly drug treating RA (van Roon et al. 2009). Methotrexate is a substrate of the 
human transporters OAT1, OAT3, MRP2 and BCRP which all-mediate active renal 
elimination. AZD9056 can’t inhibit OAT1 and OAT3 transporting methotrexate, but have a 
weakly inhibition effect on BCRP mediated transporting (IC50=92 μM) (Elsby et al. 2011). 
Recently, Keystone and colleagues have reported their work on phase Ⅱ studies, which 
assess the effects of orally administered AZD9056 on the signs or symptoms of rheumatoid 
arthritis (RA). They used randomized, double blind, placebo-controlled, and parallel-group 
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Fig. 4. Structures of P2X receptors antagonists. A-317491 which is the first non-nucleotide 
antagonist, has high selectivity (IC50 > 10 μM) to P2X3 and P2X2/3 receptors; the R-
enantiomer of A-317491, A-317344, was ineffective (ED50 > 100 μmol/kg s.c.) in neuropathic 
and inflammatory animal pain models; 3-((5-(2,3-dichlorophenyl)-1H-tetrazole-1-yl)methyl 
pyridine (A-438079) effectively inhibit Bz-ATP stimulation for P2X7 receptors; A-740003  
((N-(1-{[(cyanoimino) (5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2- (3,4-
dimetho- xyphenyl)acetamide)  shows highly specific and potent for rP2X7 and hP2X7 of 
which potency is 18-40 nM (Honore et al. 2006); Brilliant Blue G is a more potent and 
selective antagonist, IC50 for rat and human P2X7 receptor is 10 nM and 200 nM, respectively 
(North 2002); KN62 (1-[N,O-bis(5-isoquinoline-sulfonyl)-N-methyl-L-tyrosyl]-4-phe- 
nylpiperazine) which is isoquinoline derivative (Humphreys et al. 1998), inhibit ATP –
stimulated Ca2+ influx and selectively inhibit calcium/calmodulin-dependent protein kinase 
II. TNP-ATP, PPADS and suramin is non-selective antagonist at P2X receptors; ATP 2’,3’-
dialdehyde (oxidized-ATP, oATP) is a irreversible antagonist at P2X7, P2X1 and P2X2 
receptor (Di Virgilio 2003); Ip5I is a potent and selectivity antagonist for recombinant rat 
P2X1 receptors at nanomolar concentration (pIC50 = 5.6) (King et al. 1999). 
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in the phase Ⅱa and phase Ⅱb studies. Through months studies, they found out that 65% of 
patients who received 400 mg/day which is a tolerated dose responded at the ACR 20 level 
that is American College of Rheumtology 20% response criteria, comparing with 27% of 
placebo-treated recipients. In Ⅱb studies 383 randomized patients who received AZD9056 
had no clinically or statistically significant effects on RA compared with placebo group. But 
in both studies, AZD9056 was used in tolerated dose (400 mg/day) so that the proportion of 
patients meet the ACR20 criteria. The results showed that AZD9056 does not have 
significant efficacy for RA (Keystone et al. 2011). 
In 2006, Abbott Laboratories disclosed two series P2X7 antagonists: disubsituted tetrazaled 
and cyanoguanidines, which show enhanced potency and selectivity to rP2X7 and hP2X7 
(Honore et al. 2006, Nelson et al. 2006). 1-Benzyl-5-aryltetrazoles were discovered to be 
novel P2X7 antagonists by Nelson et al (Nelson et al. 2006). 3-((5-(2, 3-dichlorophenyl)-1H-
tetrazole-1-yl) methyl pyridine (A-438079) effectively inhibits Bz-ATP stimulation. The 
compound can inhibit calcium flux in human and rat P2X7 cell lines. It’s IC50 for human and 
rat P2X7 receptors are 100 and 300 nM respectively. It has devoid activity to other P2 
receptors (IC60>> 10 μM) and its analogues can also have the ability to inhibit IL-1ǃ release 
and P2X7 mediated pore formation in human THP-1 cells (Nelson et al. 2006). Daniel 
Marcellino et al using P2X7 receptor antagonist A-438079 as a tool found out that blockade 
of P2X7 might be a novel protection strategy for striatal DA terminals in Parkinson’s disease 
(Marcellino et al. 2010). Mcgaraughty et al utilized A-438079 investigate P2X7 related 
antinociception mechanism in vivo and vitro. Three different rat models of neuropathic pain 
showed attenuated formalin-induced nocifensive behaviors after injecting 10-300 μmol/kg 
(i.p.) of A-438079 (McGaraughty et al. 2007). A-438079 dose dependently (0.3-3μM) 
decreased the quantity of cytokine and IL-1ǃ (McGaraughty et al. 2007). Comparing other P2 
receptors, A-740003 ((N-(1-{[(cyanoimino) (5-quinolinylamino) methyl] amino}-2, 2-
dimethylpropyl)-2-(3, 4-dimetho- xyphenyl) acetamide) shows highly specific and potent 
effects on rP2X7 and hP2X7 of which potency is 18-40 nM (Honore et al. 2006). It also changes 
intracellular calcium concentration in a competitive way. Both compounds’ sufficient 
bioavailability in intraperitoneal administration allows for in vivo investigation on disease 
models of P2X7 receptors (Honore et al. 2006, Nelson et al. 2006). 
Suramin (IC50> 300 μM for rat P2X7) and PPADS (IC50～50 μM) (pyridoxalphosphate- 6-
azopheny2’, 4’-disulfonate) are both prototypic nonselective P2X receptor antagonists 
(North 2002). They show noncompetitive antagonism and low affinity (Ki>10 μM). KN62 (1-
[N,O-bis(5-isoquinoline-sulfonyl) -N-methyl-L-tyrosyl]-4-phe-nylpiperazine) which is 
isoquinoline derivative (Humphreys et al. 1998), and being a most potent compound with 
13.4 nM IC50, can inhibit ATP–stimulated Ca2+ influx and selectively inhibit 
calcium/calmodulin-dependent protein kinase II. But it shows significantly species 
differences. It is more potent to human P2X7 versus rat P2X7 (Humphreys et al. 1998). 
Brilliant Blue Gis a more potent and selective antagonist, IC50 for rat and human P2X7 
receptor is 10 nM and 200 nM, respectively (North 2002). 
Michel et al reported the decavanadate, which is a polymeric form of vanadate, is a 
reversible and competitive P2X7 receptor antagonist. But it also displays non-selectivity 
because it not only inhibits the P2X2 and P2X4 mediated response, but also interacts with IP3 
binding and inhibition of ribonuclease A (Michel et al. 2006).  
ATP 2’, 3’-dialdehyde (oxidized-ATP, oATP), ATP with the 2’- and 3’-hydroxyl moieties 
oxidized to aldehydes by periodate treatment, is a irreversible antagonist required 1 or 2 h 
incubation to inhibit P2X7 receptor (Di Virgilio 2003). oATP is used in mouse macrophage to 
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lock P2X7 initiated responses. But except that, oATP can also inhibit P2X1 and P2X2 mediated 
responses (Evans et al. 1995). It also inhibits nuclear factor-κB (NF-κB) and cytokine release. 
So these limit its role as a pharmacological tool like decavanadate. 
4.2 P2X3 and P2X2/3 receptors 
P2X3 and P2X2/3 receptors localize on peripheral and central processes of sensory afferent 
nerves (Jarvis et al. 2002). Experiment with antisense oligonucleotides and P2X3 knockout 
mice proved that P2X3 receptors play a crucial role in the signaling of chronic inflammatory 
pain and some features of neuropathic pain.  
Virginio et al. identified 2’3’-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP) can block P2X1, P2X3 
and P2X2/3 receptors, but it is ineffective in blocking currents produced by activated P2X2, 
P2X4 and P2X7 receptors. It can completely block fast component of ATP mediated and 
ǂǃmeATP mediated sustained current in neurones of dorsal root and nodose ganglia 
(Bradbury et al. 1998). It is a competitive antagonist for P2X3 and P2X2/3 receptors with pA2 
values of -8.7 and -8.2 (Burgard et al. 2000). The IC50 values for hP2X2/3 and rP2X2/3 are 3 to 6 
nM. It displays a rapid inhibition in onset, reversible, and use independence. The P2X2/3 
receptors can fully recover from TNP-ATP after removal it for more than 5 s (Burgard et al. 
2000). 
A-317491 has high selectivity (IC50> 10 μM) to P2X3 and P2X2/3 receptors, which can potently 
block human and rat P2X3 and P2X2/3 mediated calcium flux (Ki=22 – 92 nM) (Jarvis et al. 
2002). Using neuropathic and inflammatory animal pain models, A-317491 can reduce 
nociception. They use s.c. administration found out that A-317491 dose-dependently (ED50 = 
30 μmol/kg s.c.) reduced complete Freund's adjuvant-induced thermal hyperalgesia in the 
rat pain models, but ineffective in acute pain, postoperative and visceral pain (Jarvis et al. 
2002). However, it is most effective (ED50 = 10 - 15μmol/kg) in attenuating both 
thermahyperalgesia and mechanical allodynia after chronic nerbe constriction injury. On the 
contrary, the R-enantiomer of A-317491, A-317344, was ineffective (ED50 > 100 μmol/kg 
s.c.)in neuropathic and inflammatory animal pain models. Nakagawa et al use the pain 
animal models found out that i.t. co-administration of ATP and A-317491 (30 nM) 
significantly prevented the ATP-induced allodynia (Nakagawa et al. 2007). In other drug 
treatment group, co-administration of suramin and PPADS significantly prevented the 
induction of longlasting allodynia (Nakagawa et al. 2007). 
AF-353, which is synthesized by Roche Palo Alto are novel, selective and highly potent P2X3 
and P2X2/3 receptor antagonist. It has been proved that AF-353 is orally bioavailable (%F = 
32.9) and stable in vivo for the treatment of pain which is in clinical trial (Gever et al. 2010). 
The antagonistic potencies (pIC(50)) for rat and human P2X3 and human P2X2/3 receptors 
ranged from 7.3 to 8.5 which had little or no effect on other P2X receptors (Gever et al. 2010). 
Comparing with A-317491 and TNP-ATP, AF-353 inhibits activation by ATP in non-
competitive fashion. It is observed that A-317491 has reasonable half-life (t(1/2) = 1.63 h) and 
plasma-free fraction (98.2% protein bound) (Gever et al. 2010). This compound is good for 
studying P2X3 and P2X2/3 receptors in animal models and optimize compound for clinic trial. 
4.3 P2X4 receptors 
Finding antagonists for the P2X4 receptor has been more problematic. Suramin, PPADS and 
reactive Blue 2 are conventional non-selective antagonists for P2X4 receptors up to present. 
PPADS is a reversible antagonist required 20 to 30 min washing can partially reverse (North 
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2002). The hP2X4 receptor is more sensitive to PPADS than rP2X4. Jones et al reported that 
IC50 for mouse P2X4 receptor is 10 mΜ (Jarvis et al. 2002, Jones et al. 2000). Recently 
Wilkinson and Kemp proved that CORMs which is co-releasing molecules is an effective 
antagonist at human P2X4  receptors (Jarvis et al. 2002).  
4.4 P2X1 receptors 
Diinosinepentaphosphate (IpnI, n is the number of phosphates), comprise two 
ribosylatedinosine molecules bridged by a phosphate chain. These dinucleotides are 
synthesized by deaminating diadenosine polyphosphates with non-specific AMP-
deaminase of Aspergillus sp. (Pintor et al. 1997). P1,P5-bis(5’-inosyl) pentaphosphate (Ip5I), 
the member of this family, has been showing a potent antagonist at a specific dinucleotide 
receptor in rat brain synaptosomes (IC50 = 4 nM) and P2X receptor (IC50 = 30 μM) (Pintor et 
al. 1997). King et al. reported that Ip5I is a potent and selectivity antagonist for recombinant 
rat P2X1 receptors at nanomolar concentration (pIC50 = 5.6). Non-linear of Schild plot proved 
that Ip5I is a noncompetitive antagonist (King et al. 1999). It represents a different manner in 
low and high concentrations. At low (≤ 100 nM) concentrations Ip5I represents a high 
affinity antagonist for P2X1 receptors, however, in higher (> 100 nM) concentrations it 
represent a more complex actions. 
Jacobson et al. synthesize two antagonists which are analogues of PPADS. MRS 2220 is 
selective antagonist. Comparing with PPADS (IC50 = 98.5 +/- 5.5 nM), MRS 2220 represents 
a lower IC50 (IC50 = 10.2 +/- 2.6 mM) at recombinant P2X1 receptor, But unlike PPADS its 
effect was reversible with washout and surmountable (Jacobson et al. 1998).  
NF023 (8, 8’-(carbonylbis (imino-3, 1-phenylene carbonylimino) bis (1, 3, 5-
naphthalenetrisulf onic acid)) is suramin analogue, which represent a competitive fashion at 
P2X receptor-mediated responses in certain vascular and visceral smooth muscles. P2X1 
receptors represent a most sensitive manners with IC50 values of 0.24 and 0.21 μM for rat 
and human homologues, respectively (Soto et al. 1999). P2X2 (IC50> 50 μM), P2X3 (IC50 = 8.5 
and 28.9 μM for rat and human), P2X4 (up to 100 μM) shown different sensitivity (Soto et al. 
1999). TNP-ATP is potent antagonist at P2X1 and P2X3 receptors at nanomolar 
concentrations. 
4.5 Other P2X receptors 
So far, there is no selective and potency antagonists that is orally bioavailable and stable in 
vivo for P2X2, P2X5 and P2X6. Suramin, PPADS and TNP-ATP are non-selective antagonists 
at P2X receptors. Seven P2X receptors represent different sensitivity.  
5. Conclusion and future issues 
P2X receptor, which is a novel family of ligand-gated cation channels, is non-selective cation 
channel that gated in the presence of ATP. Seven P2X receptor subunits (P2X1-7) are widely 
distributed in excitable and non-excitable cells of vertebrates and play a crucial role in inter 
alia afferent signaling (including neuropathic pain), regulation of renal blood low, vascular 
endothelium, and chronic inflammation. Thus P2X receptors are potential targets for drug 
development. The field is still limited by the availability of agonist, antagonist and 
modulator which could accelerate our understanding of the physiological roles of P2X 
receptors. However, there are some notable antagonists of P2X1, P2X3 and P2X7 receptors 
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with highly potency, selectivity and nanomolar affinity, such as AF-353, A-317491 and 
AZD9056. There are some important issues for the antagonist application. The first is actions 
at receptors other than P2X receptors. If the antagonist is developed to be a potential drug, it 
has to overcome the actions on other receptors or other subtype of P2X receptors. Selectivity 
is important for drug development. For example, TNP-ATP, PPADS and suramin are non-
selective antagonists of P2X receptors. Seven subtypes of P2X receptors represent different 
sensitivity. But it would be welcomed to study the physiological and functional role for 
developing such compounds. The second is the species specificity. Human and rat P2X 
receptors represent different sensitivity to a compound which means that it is difficult to do 
animal model experiments before the clinic trial. So far, there has been promising 
development of clinical P2X7 antagonists, notably Abbott compounds – A-438079 and A-
740003. Both compounds represent highly specificity and potency for rP2X7 and hP2X7. 
Sufficient bioavailability is likely to allow for in vivo investigation on disease models of 
P2X7 receptors. Another promising P2X7 receptor antagonist is AZD9056, which was 
developed for oral treatment of rheumatoid arthritis. But recent clinical trail II experiments 
showed that AZD9056 did not have significant efficacy for RA. They concluded that P2X7 
receptors do not appear to be a therapeutically useful target in RA. However, it is proved 
that AZD9056 is a selective and potent antagonist of P2X7 receptors before clinical trial II. So 
it might be efficacious for other diseases which are related to P2X7 receptors. AF-353 is most 
promising compound that may reach the market introduction. The good orally bio-
availability and stability of AF-353 in vivo may bring the biggest advantage for patients in 
pain treatment. Antagonists for some of the other P2X receptors remain to be developed. 
P2X receptors are likely to have widespread therapeutic usage in the future. 
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